Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1990 3
1991 2
1992 2
1994 4
1995 1
1996 1
1997 1
1998 1
1999 1
2000 1
2001 1
2002 4
2003 1
2004 1
2005 4
2006 4
2007 9
2008 15
2009 17
2010 18
2011 32
2012 30
2013 24
2014 23
2015 32
2016 24
2017 26
2018 35
2019 46
2020 57
2021 86
2022 69
2023 85
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

601 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine Use for Cancer and Chronic Pain Management.
Culp C, Kim HK, Abdi S. Culp C, et al. Front Pharmacol. 2021 Feb 2;11:599721. doi: 10.3389/fphar.2020.599721. eCollection 2020. Front Pharmacol. 2021. PMID: 33708116 Free PMC article. Review.
Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. ...
Ketamine, an N-methyl-D-aspartate receptor antagonist, is widely known as a dissociative anesthetic and phencyclidine derivative. ...
Shattering barriers toward clinically meaningful MSC therapies.
Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, Karp JM. Levy O, et al. Sci Adv. 2020 Jul 22;6(30):eaba6884. doi: 10.1126/sciadv.aba6884. eCollection 2020 Jul. Sci Adv. 2020. PMID: 32832666 Free PMC article. Review.
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R. Jiang L, et al. Cell. 2020 Nov 25;183(5):1219-1233.e18. doi: 10.1016/j.cell.2020.10.045. Cell. 2020. PMID: 33242418 Free PMC article.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Albiges L, et al. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. Lancet Oncol. 2023. PMID: 37451291 Clinical Trial.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progression-free survival of 6.6 months (6.1-9.3) and overall survival of 15.1 months (11.3-18.7). ...Treatment-related deaths occurred in ten (3%) of 356 patients treated with cemipl …
Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progression-free survival of 6.6 months (6. …
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Gümüş M, et al. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477. Epub 2022 Oct 29. Cancer. 2023. PMID: 36308296 Free PMC article. Clinical Trial.
Kaplan-Meier analysis estimated time to definitive deterioration. RESULTS: In PD-L1 50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ-C30 and QLQ-LC13 scores showed moderate-to-high functioning and low symptom burden. ...
Kaplan-Meier analysis estimated time to definitive deterioration. RESULTS: In PD-L1 50% patients (cemiplimab, n = 283; chemotherapy, …
Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice.
Zhao J, Jung S, Li X, Li L, Kasinath V, Zhang H, Movahedi SN, Mardini A, Sabiu G, Hwang Y, Saxena V, Song Y, Ma B, Acton SE, Kim P, Madsen JC, Sage PT, Tullius SG, Tsokos GC, Bromberg JS, Abdi R. Zhao J, et al. J Clin Invest. 2022 Dec 15;132(24):e159672. doi: 10.1172/JCI159672. J Clin Invest. 2022. PMID: 36519543 Free PMC article.
601 results